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Lgals9 deficiency ameliorates 
obesity by modulating redox state 
of PRDX2
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The adipose tissue is regarded as an endocrine organ and secretes bioactive adipokines modulating 
chronic inflammation and oxidative stress in obesity. Gal-9 is secreted out upon cell injuries, interacts 
with T-cell immunoglobulin-3 (Tim-3) and induces apoptosis in activated Th1 cells. Gal-9 also binds 
to protein disulfide isomerase (PDI), maintains PDI on surface of T cells, and increases free thiols 
in the disulfide/thiol cycles. To explore the molecular mechanism of obesity, we investigated Gal-
9−/− and Gal-9wt/wt C57BL/6J mice fed with high fat-high sucrose (HFHS) chow. Gal-9−/− mice were 
resistant to diet-induced obesity associated with reduction of epididymal and mesenteric fat tissues 
and improved glucose tolerance compared with Gal-9wt/wt mice. However, the number of M1, M2 
macrophages, and M1/M2 ratio in epididymal fat were unaltered. Under HFHS chow, Gal-9−/− mice 
receiving Gal-9−/− or Gal-9wt/wt bone marrow-derived cells (BMCs) demonstrated significantly lower 
body weight compared with Gal-9wt/wt mice receiving Gal-9−/− BMCs. We identified the binding 
between Gal-9 and peroxiredoxin-2 (PRDX2) in sugar chain-independent manner by nanoLC-MS/
MS, immunoprecipitation, and pull-down assay. In 3T3L1 adipocytes, Gal-9 knockdown shifts PRDX2 
monomer (reduced form) dominant from PRDX2 dimer (oxidized form) under oxidative stress with 
 H2O2. The inhibition of Gal-9 in adipocytes may be a new therapeutic approach targeting the oxidative 
stress and subsequent glucose intolerance in obesity.
The obesity is now pandemic in worldwide and the data from WHO demonstrated that more than 1.9 bil-
lion adults were overweight and over 650 million obese in 2016 (https ://www.who.int/news-room/fact-sheet s/
detai l/obesi ty-and-overw eight ). It substantially increases the risk of diseases such as type 2 diabetes, fatty liver 
disease, dyslipidemia and  hypertension1. The adipose tissue has been regarded as an endocrine organ and it 
secretes bioactive adipokines leading to low grade chronic inflammation and amplification of oxidative  stress2. 
In the obese patients, the chronic inflammation is demonstrated by the elevation of high-sensitive C-reactive 
 protein3, interleukin (IL)-63, IL-10, and tumor necrosis factor α (TNF-α)4, while the oxidative stress revealed by 
decreased antioxidant enzymes (catalase, glutathione peroxidase, superoxide dismutase)5 or increased levels of 
 malondialdehyde3,5, urinary 8-hydroxy-2′-deoxyguanosine6 and lipid peroxidation markers (8-iso-prostaglandin 
F2α)7. By targeting inflammation and oxidative stress in obese patients, the interventions with foods and sup-
plements in a randomized controlled trial have been conducted, such as Mediterranean diet with extra virgin 
olive  oil6, pigmented  rice8, Baru  almonds5, and  curcumin3. Although life-style modifications and intervention 
with foods and supplements have been vigorously attempted, the mechanism for the inflammation and oxidative 
stress in obesity is not fully explored.
Galectin-9 (Gal-9) is consisted of N- and C-terminal carbohydrate binding domains, which recognize 
β-galactoside sugar  structure9,10. Gal-9 is found to be involved in intracellular and extracellular processes, such as 
glycoprotein trafficking, cell–cell or cell-extracellular matrix interaction, signal transduction, immune response, 
development and  oncogenesis11. Gal-9 is induced by various stimuli such as interferon-γ, IL-1β, toll-like recep-
tor agonists, several different  viruses12,13, and Leishmania  parasites14. Gal-9 is secreted out from cytoplasm 
to extracellular space in non-classical secretion pathway as damage-associated molecular patterns (DAMPs) 
or pathogen-associated molecular patterns (PAMPs)14–16. Secreted Gal-9 interacts as a ligand with N-glycans 
covalently attached to the surface of T-cell immunoglobulin-3 (Tim-3)17. Gal-9 triggers a series of events like 
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calcium mobilization, calpain and caspase-1 activation and drives the Th1 cells to apoptosis. The injection of 
recombinant Gal-9 induced the apoptosis of T cells and ameliorated the diseases such as nephrotoxic  nephritis18, 
type 1  diabetes19, and systemic lupus erythematosus (SLE)20. Tim-3 and Gal-9 are also targets for the immune 
checkpoint inhibition immunotherapies for  cancers21. Although the roles of Gal-9 in immune response such as 
the apoptotic potential against Tim3 + Th1,  Th1722, Tim-3 +  NKT23, and  CD824 cells are well-investigated, the 
functional role of Gal-9 in oxidative stress and redox status is totally unexplored. Recently, Gal-9 is reported to 
retain protein disulfide isomerase (PDI) on cell surface of T cells by binding to O-glycans on PDI. PDI creates 
disulfide bonds in nascent protein and shifts the disulfide/thiol equilibrium on the T cell  surface25.
The adipose tissues in obesity represent chronic inflammation characterized by Th1/M1-macrophage domi-
nant versus Th2/M2  cells26. In addition, the oxidative stress is critically involved of development of metabolic 
syndrome phenotype in  obesity27. To explore the molecular mechanism of inflammation and oxidative stress in 
obesity, we investigated the  Lgals9tm1Glp/Lgals9tm1Glp (Gal-9−/−) C57BL/6J mice fed with high fat-high sucrose diet 
(HFHS) and analyzed the phenotypes. Here, we demonstrate Gal-9−/− C57BL/6J mice are resistant to diet-induced 
obesity independent of bone marrow-derived cells. We also show that Gal-9 binds to peroxiredoxin-2 (PRDX2) 
and Gal-9 knockdown shifts PRDX2 monomer (reduced form) dominant against PRDX2 dimer (oxidized form) 
under oxidative stress.
Results
Gal-9 deficiency contributes the resistance to obesity. Under standard (STD) chow, there was no 
difference in body weights between Gal-9−/− (29.4 ± 2.4 g) and Gal-9wt/wt mice (30.8 ± 1.4 g) at 28 weeks (p = 0.999) 
(Fig. 1a). After the initiation of HFHS chow, Gal-9−/− mice gained less body weight (41.2 ± 4.5 g) compared with 
Gal-9wt/wt mice (43.5 ± 0.9 g) and it was statistically significant at 28 weeks of age (p = 2.16 ×  10–7) (Fig. 1a). Under 
HFHS chow at 28 weeks of age, the fat pad weights of visceral white adipose tissues (WATs) were also lower in 
Gal-9−/− mice compared with Gal-9wt/wt mice in epididymal (1.13 ± 0.52 g vs. 2.03 ± 0.42 g, p = 2.2 ×  10–4), mes-
enteric (0.30 ± 0.21 g vs. 0.60 ± 0.31 g, p = 0.007), retroperitoneal (0.54 ± 0.40 g vs. 0.77 ± 0.22 g, p = 0.092), and 
subdermal (0.89 ± 0.68 g vs. 1.14 ± 0.26 g, p = 0.273) WATs (Fig. 1b), respectively. Although the mass of WATs was 
reduced in in Gal-9−/− mice fed with HFHS chow, the size of adipocytes and frequency of crown-like structure 
were not altered in Gal-9−/− mice compared with Gal-9wt/wt mice (Fig. 1c). In contrast to WATs, there were no 
apparent changes in liver weight, size and distribution of lipid droplets in hepatocytes, tissue cholesterol and 
triglyceride contents in liver tissues in Gal-9−/− mice fed with HFHS chow (Fig. 2a,b).
Glucose and lipid metabolism are improved in Gal‑9−/− mice. The intraperitoneal glucose tolerance 
tests (IPGTT) were performed during 20–22 weeks of age. The IPGTT demonstrated that blood glucose lev-
els were significantly lower in Gal-9−/− mice fed with HFHS chow compared with Gal-9wt/wt mice in the fast-
ing and during the test period (Fig.  3a). During IPGTT, plasma insulin levels revealed lower tendency in 
Gal-9−/− mice compared with Gal-9wt/wt mice fed with HFHS chow, although it was not statistically significant 
(Fig. 3b). At 28 weeks of age, fasting serum levels of total cholesterol and triglyceride demonstrated no changes 
in Gal-9−/− mice compared with Gal-9wt/wt mice fed with HFHS chow (Fig. 3c). However, non-esterified free 
fatty acids (NEFA) (0.67 ± 0.15 vs. 1.15 ± 0.24 mEq/L) and serum leptin levels (3.23 ± 4.86 vs. 30.4 ± 6.80 ng/mL, 
p = 5.0 ×  10–6) were significantly reduced in Gal-9−/− mice compared with Gal-9wt/wt mice fed with HFHS chow 
(Fig. 3c). Interestingly, Lgals9 deficiency exhibited beneficial effects of up-regulated serum levels of adiponectin 
under STD chow; however, such effects were cancelled under HFHS chow (Fig. 3c). To investigate the energy 
expenditure, oxygen consumption rate ( ̇V ̇O2) and respiratory quotient (RQ) were measured. V̇ ̇O2 was signifi-
cantly increased in Gal-9−/− mice (3613 ± 350 mL/min/hr) compared with Gal-9wt/wt mice (2992 ± 283 mL/min/
hr) fed with HFHS chow (p = 0.011) RQ remained in similar levels in both Gal-9−/− mice (0.77 ± 0.04) and Gal-
9wt/wt mice (0.76 ± 0.03) fed with HFHS chow (Fig. 3d). Locomotor activities, the intake of STD and HFHS chow 
were also similar in both groups (Fig. 3e,f).
Contribution of inflammatory cells for the protection of obesity in Gal‑9−/− mice is minimal. Since 
the injection of recombinant Gal-9 into mice induces the apoptosis of activated T-cell immunoglobulin mucin-3 
(Tim-3) positive Th1 cells, we initially hypothesized that the deficiency of Gal-9 may further shift M1/M2 bal-
ance of the adipose tissue macrophages to M1 polarization. First, we investigated the gene expression profile 
of M1 and M2 macrophage markers using total RNA isolated from whole epididymal adipose tissues. Under 
HFHS chow, the M1 markers including Il6, Il10, Nos2, and Tnf increased except for Il18, while M2 markers such 
Arg1 and Ym1 were reduced compared with STD chow groups in both Gal-9wt/wt and Gal-9−/− mice, although 
statistically significant changes were observed only in Il6 and Arg1. There were no differences in both M1 and 
M2 markers between Gal-9wt/wt and Gal-9−/− mice fed with HFHS chow (Supplementary Fig. 1a). Next, we inves-
tigated the population of M1 and M2 macrophages in stromal vascular fractions (SVF) from epididymal fat pads 
by FACS analyses. F4/80 + CD11b + /CD45.2 + (macrophages) and CD11c + CD206-/F4/80 + CD11b + (M1 mac-
rophages) increased, while CD11c-CD206 + /F4/80 + CD11b + (M2 macrophages) decreased in both Gal-9wt/wt 
and Gal-9−/− mice. Again, there were no differences of M1/M2 ratios between Gal-9wt/wt and Gal-9−/− mice fed 
with HFHS chow (Supplementary Fig. 1b). We next tried to clarify whether the absence of Gal-9 in inflamma-
tory cells or in adipocytes contributed the obesity-resistant phenotypes in Gal-9−/− mice fed with HFHS chow. 
We performed bone marrow transplantation experiments, and 4–6 weeks old Gal-9wt/wt and Gal-9−/− recipient 
mice were injected with bone marrow cells (BMCs) derived from Gal-9wt/wt and Gal-9−/− mice. They were fed 
with HFHS chow and body weight was measured for 16 weeks (Fig. 4). Transplantation of Gal-9−/− BMCs did 
not reduce the body weight of Gal-9wt/wt mice fed with HFHS chow (Fig. 4a). Furthermore, Gal-9−/− mice fed 
with HFHS chow did not gain weight by the transfusion of Gal-9wt/wt BMCs (Fig. 4b). The data suggested that the 
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deficiency of Gal-9 in BMCs did not contribute the reduction of body weight in the mice fed with HFHS chow. 
In contrast, the body weight of Gal-9−/− recipient mice was always lower than Gal-9wt/wt recipient mice fed with 
HFHS chow under the presence or absence of Gal-9 gene in BMCs (Fig. 4c–f). Under HFHS chow, Gal-9−/− mice 
receiving Gal-9−/− or Gal-9wt/wt BMCs demonstrated significantly lower body weight compared with Gal-9wt/wt 
mice receiving Gal-9−/− BMCs (Fig. 4c) or Gal-9wt/wt BMCs (Fig. 4d).
The identification of Gal-9 interacting proteins in adipocytes. Bone marrow transplantation exper-
iments suggested that the absence of Gal-9 in adipocytes may contribute the resistance to obesity and insulin 
resistance in Gal-9−/− mice. To identify the Gal-9 interacting proteins in adipocytes, the immunoprecipitated 
protein complexes by monoclonal anti-Gal-9 antibody or isotype control isolated from epididymal fat pads in 
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Figure 1.  Body and fat pad weights and histology of epididymal adipose tissues. (a) Body weight in Gal-9wt/wt 
and Gal-9−/− mice fed with standard (STD) and high fat-high sucrose (HFHS) chow. Gal-9wt/wt (STD), n = 9; Gal-
9−/− (STD), n = 10, Gal-9wt/wt (HFHS), n = 9; Gal-9−/− (HFHS), n = 12. *, p < 0.05; **, p < 0.01 [Gal-9wt/wt (HFHS) 
vs. Gal-9−/− (HFHS)]; †, p < 0.05; ††, p < 0.01 [Gal-9wt/wt (STD) vs. Gal-9wt/wt (HFHS)]. One-way ANOVA 
with Tukey–Kramer. (b) Fat pad weight. Gal-9wt/wt (STD), n = 9; Gal-9−/− (STD), n = 8, Gal-9wt/wt (HFHS), 
n = 8; Gal-9−/− (HFHS), n = 9. *, p < 0.05; **, p < 0.01. One-way ANOVA with Tukey–Kramer. c. PAS stain and 
immunofluorescence study. *, Crown-like structures; Green, F4/80; Red, Perilipin; Blue DAPI. Bar = 100 μm.
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isotype control antibody-precipitated proteins and the comparison of exponentially modified protein abundance 
index (emPAI) values of proteins between 2 samples were listed in Supplementary Table  1a–c. The proteins 
found only in anti-Gal-9 antibody- and isotype control antibody-precipitated samples are shown in Supplemen-
tary Table 1d, e, respectively. Since the absence of intracellular Gal-9 may be involved in the amelioration of obe-
sity, the intracellular proteins were firstly screened. The proteins found only in anti-Gal-9 antibody-precipitated 
sample were subjected to gene ontology analysis by PANTHER 15.0 (Supplementary Table 2). Gal-9, perox-
iredoxin 2 (PRDX2), serine/threonine-protein kinase RIO2, ATP-citrate synthase, cytosolic phospholipase A2 
zeta, and serine/threonine-protein kinase WNK1 were identified as cytosolic protein (Supplementary Table 2). 
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Figure 2.  Histology of the liver, weight, cholesterol, and triglyceride contents. (a) PAS staining of the liver. 
There are no differences in lipid droplets in the liver. (b) Liver weight, cholesterol and triglyceride contents. 
Gal-9wt/wt (STD), n = 8; Gal-9−/− (STD), n = 5, Gal-9wt/wt (HFHS), n = 7; Gal-9−/− (HFHS), n = 5 in liver weight. 
Gal-9wt/wt (STD), n = 5; Gal-9−/− (STD), n = 6, Gal-9wt/wt (HFHS), n = 5; Gal-9−/− (HFHS), n = 6 in cholesterol and 
triglyceride contents. *, p < 0.05; **, p < 0.01. One-way ANOVA with Tukey–Kramer.
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Figure 3.  Glucose, lipid metabolism, and energy expenditures. (a) Blood glucose levels in intraperitoneal 
glucose tolerance tests (IPGTT; 1 mg/g weight) at 20–22 weeks of age. Gal-9wt/wt (STD), n = 11; Gal-9−/− 
(STD), n = 12, Gal-9wt/wt (HFHS), n = 11; Gal-9−/− (HFHS), n = 13. *, p < 0.05; **, p < 0.01 [Gal-9wt/wt (HFHS) 
vs. Gal-9−/− (HFHS)]; †, p < 0.05; ††, p < 0.01 [Gal-9wt/wt (STD) vs. Gal-9wt/wt (HFHS)]. One-way ANOVA with 
Tukey–Kramer. (b) Plasma insulin concentration in intraperitoneal glucose tolerance test. Gal-9wt/wt (STD), 
n = 8; Gal-9−/− (STD), n = 5, Gal-9wt/wt (HFHS), n = 7; Gal-9−/− (HFHS), n = 5. †, p < 0.05; ††, p < 0.01 [Gal-9wt/wt 
(STD) vs. Gal-9wt/wt (HFHS)]. Kruskal–Wallis test with Bonferroni correction. (c) Serum levels of cholesterol, 
triglyceride, non-esterified fatty acid (NEFA), adiponectin and leptin. Gal-9wt/wt (STD), n = 4; Gal-9−/− (STD), 
n = 4, Gal-9wt/wt (HFHS), n = 4; Gal-9−/− (HFHS), n = 4. *, p < 0.05; **, p < 0.01. (d) Oxygen consumption rate ( ̇V
Ȯ2) and respiratory quotient (RQ). Gal-9wt/wt (STD), n = 3; Gal-9−/− (STD), n = 6, Gal-9wt/wt (HFHS), n = 4; Gal-
9−/− (HFHS), n = 6. **, p < 0.01. (e) Locomotor activities during light and dark periods. Gal-9wt/wt (STD), n = 3; 
Gal-9−/− (STD), n = 4, Gal-9wt/wt (HFHS), n = 4; Gal-9−/− (HFHS), n = 5. (f) Chow intake. Gal-9wt/wt (STD), n = 3; 
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mitochondrial oxidative stress in adipocytes is known to cause insulin resistance, and 6 mitochondrial proteins, 
electron transfer flavoprotein subunit alpha (ETFA), ferredoxin-2, 3-ketoacyl-CoA thiolase (ACAA2), long-
chain specific acyl-CoA dehydrogenase (ACADVL), acyl-CoA dehydrogenase family member 9 (ACAD9), and 
carnitine O-palmitoyltransferase 2 (CTP2), were also listed in the proteins found only in anti-Gal-9 antibody-
precipitated sample (Supplementary Table 1d and 2).
Gal-9 binds to PRDX2 and its dimer/monomer ratio is reduced by Gal-9 siRNA. Mitochondria 
are major source of oxidative stress in adipocytes under obesity and insulin resistance state, and peroxiredoxins 
are important for antioxidant responses against oxidative stress, we further investigated whether Gal-9 interacts 
with peroxiredoxins and mitochondrial proteins. Among peroxiredoxins 1, 2, 3, 4, and 5, Gal-9 was detected 
in the protein complexes immunoprecipitated by anti-PRDX2 antibody in the lysates isolated from epididymal 
adipose tissues of Gal-9wt/wt mice (Supplementary Fig. 2). Total lysate of 3T3L1 cells without plasmid transfec-
tion was applied to Anti-HA tag Beads and Gal-9 was detected by Western blot analysis (Supplementary Fig. 3a, 
lane 4). However, the binding between Gal-9 and Beads was completely inhibited by the addition of 0.2 M lactose 
(Fig. 5a, lane 4, Supplementary Fig. 4a). Thus, following experiments were performed in the presence of 0.2 M 
lactose. PRDX2-FLAG-HA-pcDNA3.1 (PRDX2) and FLAG-HA-pcDNA3.1 (HA) were transfected into 3T3L1 
cells, and total cell lysates were subjected to Anti-HA tag Beads isolation and Western blot analysis. Gal-9 and 
HA-tagged PRDX2 and were detected in protein complexes isolated by Anti-HA tag Beads (Fig. 5b and Supple-
mentary Fig. 4b). Although anti-thioredoxin (TRX) antibody cross-reacted to HA-tagged PRDX2, native TRX 
was not detected in the HA-tag purified protein complexes (Fig. 5c and Supplementary Fig. 4c). The binding 
between Gal-9 and PRDX2 is sugar chain-independent, since the addition of 0.2 M lactose, which interrupts 
the binding between Gal-9 and β-galactoside sugar, did not inhibit the complex formation between Gal-9 and 
HA-tagged PRDX2.
Two Cysteine residues of PRDX2 form disulfide-linked homodimers upon oxidation by hydroperoxides such 
as  H2O2, and they were slowly reduced to their monomers by thioredoxin and thioredoxin oxidase system. Thus, 
PRDX2 dimer/monomer ratio well-reflects cytosolic redox status and higher ratios represent oxidative state 
in the cytosol. In 3T3L1 cells, Gal-9 siRNA reduced the protein expression of Gal-9 to 42.1 ± 3.2% compared 
with NC siRNA treated cells (Fig. 5d and Supplementary Fig. 4d). Under the basal states without  H2O2, PRDX2 
dimer/monomer ratios were not altered in NC siRNA (2.12 ± 0.23) and Gal-9 siRNA (2.27 ± 0.02) treatments. 
However, in the presence of 10 μM  H2O2, the dimer/monomer ratios were reduced from 2.38 ± 0.04 to 1.88 ± 0.10 
by the treatments with Gal-9 siRNA (Fig. 5e and Supplementary Fig. 4e), suggesting that Gal-9 knockdown shifts 
the redox state to reducing conditions. We also investigated the oxidative stress signaling pathway such as p38 
mitogen-activated protein kinase (p38-MAPK), stress-activated protein kinase (SAPK)/Jun amino terminal 
kinase (JNK), and p42/p44 mitogen-activated protein kinases [MAPK; extracellular signal-regulated kinase 2/1 
(ERK2/1)]. Although the treatment with Gal9-siRNA partially reversed increased phospho/total SAPK/JNK 
and phospho/total ERK2/1 ratios by the oxidative stress under 10 μM  H2O2, they did not reach the statistical 
differences (Supplementary Fig. 5).
Discussion
Adipose tissue macrophages (ATMs) play key roles in the inflammation of adipose tissues and link to the devel-
opment of insulin resistance in obesity. The cell surface differentiation markers for M1 macrophages are CD11c, 
CD44, CD163, CD172, while those for M2 are arginase 1, CD206, and  CD30128. In the initial studies, the lean 
mice demonstrated M2 dominant phenotype in ATMs and the obese mice demonstrated M1 dominant pheno-
type, although mixed M1/M2 phenotypes were reported in later  studies29. M1 ATMs were localized to crown-like 
structures surrounding adipocytes and released high levels of proinflammatory cytokines such as IL-6, IL-8, 
and TNF-α. Th1 cells are induced by IL-12 and IFN-γ, and secrete the proinflammatory cytokines IFN-γ and 
TNF-α, which promote the differentiation of M1  macrophages28. Gal-9 is abundantly expressed and remained in 
cytoplasm in steady states; however, it is secreted out as DAMPs or PAMPs and induces prominent apoptosis of 
Th1 and Th17 cells by binding to Tim-3 as a ligand. Thus, we initially hypothesized that the deficiency of Gal-9 
in diet-induced obesity (DIO) mice would enhance the inflammation process in visceral adipose tissues associ-
ated with deteriorated obesity phenotype and insulin resistance. Unexpectedly, Gal-9−/− DIO mice demonstrate 
improved obesity and insulin resistance phenotypes without alterations in adipose tissue inflammation and 
M1/M2 polarization. Similarly, unexpected results were observed in a pristane-induced lupus model in Gal-
9−/− BALB/c  mice30. Since the injection of recombinant Gal-9 induced the apoptosis of T cells and ameliorated 
systemic lupus erythematosus (SLE) in MRL-lpr lupus-prone  mice20, we thought that Gal-9−/− BALB/c mice would 
demonstrate the aggravation of the disease. However, pristane treated Gal-9−/− BALB/c mice were protected 
from nephritis, arthritis and peritoneal lipogranuloma  formation30. The commercially available ELISA kits for 
Gal-9 detected the degradation products and measured concentrations were higher than actual concentrations 
of intact Gal-9. By the development of specific ELISA for whole and intact Gal-9, the concentration in healthy 
human subjects was 110 pg/mL (67–154 pg/mL)31. Although Gal-9 is abundantly and ubiquitously expressed 
in various organs, the physiological plasma concentration of Gal-9 is very low. The apoptotic potential of Gal-9 
was mainly demonstrated by the application of recombinant Gal-9 protein and it required much higher doses at 
pharmacological range above the physiological concentrations. Furthermore, the cross-link and lattice formation 
of the cell-surface glycoproteins, and the subsequent intracellular signaling by Gal-9 may be brought by the opti-
mum concentrations of Gal-9, but not by excess amount of Gal-932,33. Thus, the Gal-9 released from adipocytes 
in obesity may not be enough to demonstrate the potential to induce the apoptosis Th1 cells in adipose tissues.
In adipose tissues in DIO mice, the expression of Gal-1, Gal-9 in subcutaneous adipose tissues (SAT), and 
Gal-3 in SAT and visceral adipose tissues (VAT) were progressively increased. In contrast, Gal-12 declined 
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overtime in VAT of DIO  mice34. Although these galectins were expressed in both mature adipocytes and SVF, 
Gal-1 increased in adipocytes, Gal-3 and Gal-9 increased in SVF, whereas Gal-12 was dominant in  adipocytes34. 
Gal-134 ablation resulted in increased adiposity with impaired glucose metabolism and systemic inflammation. 
Gal-3 deficiency was reported to link to increased adiposity and dysregulated glucose  metabolism35 in the initial 
study; however, Gal-3 deletion resulted in the improvement of insulin resistance and hematopoietic-derived Gal-3 
was shown to cause cellular and systemic insulin  resistance36 in the later study. The ablation of Gal-12 known as 
a negative regulator of lipolysis resulted in increased mitochondrial respiration, reduced adiposity and increased 
insulin  sensitivity37, while the ablation of Gal-12 was also characterized by the M2 polarization associated with 
reduced insulin sensitivity in cultured  macophages38.
The role of secreted Gal-9 in extracellular milieu has been extensively investigated by focusing on the modula-
tion of immune function, i.e. the regulation of apoptosis and immune checkpoint; however, the cytosolic function 
of Gal-9 remains unexplored especially in the aspect of redox state of the  cells39. It is well known that galectins 
rapidly lose sugar-chain binding activities if they are not kept in reducing buffers because of cross-linking and 



































































































































































































Figure 4.  Body weight gain ratio in mice receiving bone marrow transplantation and fed with HFHS chow. The 
body weight at baseline is set as a reference. (a) WT → WT (n = 6), Gal-9wt/wt (donors) and Gal-9wt/wt (recipients); 
KO → WT (n = 8), Gal-9−/− (donors) and Gal-9wt/wt (recipients). (b) WT → KO (n = 7), Gal-9wt/wt (donors) 
and Gal-9−/− (recipients); KO → KO (n = 6), Gal-9−/− (donors) and Gal-9−/− (recipients). (c) KO → WT (n = 8), 
Gal-9−/− (donors) and Gal-9wt/wt (recipients); KO → KO (n = 6), Gal-9−/− (donors) and Gal-9−/− (recipients). 
(d) WT → KO (n = 7), Gal-9wt/wt (donors) and Gal-9−/− (recipients); KO → WT (n = 8), Gal-9−/− (donors) and 
Gal-9wt/wt (recipients). (e) WT → WT (n = 6), Gal-9wt/wt (donors) and Gal-9wt/wt (recipients); KO → KO (n = 6), 
Gal-9−/− (donors) and Gal-9−/− (recipients). (f) WT → WT (n = 6), Gal-9wt/wt (donors) and Gal-9wt/wt (recipients); 
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Figure 5.  Pull-down assay and Gal-9 siRNA experiments in 3T3L1 cells. (a) PRDX2-FLAG-HA-pcDNA3.1 (PRDX2) 
and FLAG-HA-pcDNA3.1 (HA) were transfected into 3T3L1 cells. In the presence of 0.2 M lactose, the protein complexes 
were HA-tag purified with Anti-HA tag Beads, and subjected to SDS-PAGE under reducing conditions and Western blot 
analysis. The membrane was incubated with anti-Gal-9 antibody. (b) The membrane was stripped off and incubated with 
anti-peroxiredoxin 2 (PRDX2) antibody. (c) The membranes was again stripped off and incubated with anti-thioredoxin 
(TRX) antibody. (d) 3T3L1 cells were treated with Silencer select Pre-designed siRNA Lgals9 (Gal-9 siRNA) and Silencer 
select negative control siRNA (NC siRNA) for 40 h. (e) After the treatment of 3T3L1 cells with siRNAs, the cells were further 
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are Gal-1 and Gal-2, while most others, such as Gal-3 and Gal-4, are more stable in the absence of reducing 
conditions. Since galectins are synthesized in the cytosol, which is highly reducing environment, sugar-chain 
binding activities are maintain in the cytosol. The oxidation of Gal-1 promoted the formation of the Cys16-Cys88 
disulfide bond, and multimers through Cys2 and oxidized Gal-1 did not bind to  lactose40. Interestingly, oxidized 
form of Gal-1 without lectin activity promotes the axonal regeneration, not in the reduced  form41. Similarly, the 
oxidation of Gal-2 by  H2O2 resulted in the loss of lectin activity, while treatment of Gal-2 with S-nitrosocysteine 
prevented  H2O2-induced  inactivation42. In contrast to Gal-1 and Gal-2, Gal-3 is actively involved in the regu-
lation of redox state in the patients with aortic stenosis (AS) and animal model of cardiac damage. Gal-3 was 
up-regulated in myocardial biopsy from AS patients and negatively correlated with the expression of  PRDX443. 
The inhibition Gal-3 with modified citrus pectin (MCP) exhibited dramatic improvement in cardiac function 
of the doxorubicin-treated rats by upregulating anti-oxidant  PRDX444.
Although the involvement of Gal-9 in redox regulation had been totally unknown, the role Gal-9 in cell 
surface redox control of T cells was  reported25. Thioredoxin and protein disulfide isomerase (PDI) are members 
of PDI family. PDI cleaves disulfide bonds by thiol/disulfide exchange on the plasma membrane, while PDI in 
the endoplasmic reticulum operates as an oxidase, creating disulfide  bonds25. Exogenous Gal-9 binds to PDI 
via O-glycan, maintains the retention of PDI on surface of T cells, and increases free thiols in the disulfide/thiol 
 cycles45,46. In our experiments, we firstly demonstrated that Gal-9 binds to PRDX2 independent of sugar-binding 
activity of Gal-9, since the binding was not cancelled by the addition of lactose. Two pairs of cysteine residues in 
PRDX2 form disulfide-linked homodimers in the presence of  H2O2, and they return to their monomers by thiore-
doxin and thioredoxin oxidase  system47. Higher PRDX2 dimer/monomer ratio indicates the oxidative stress and 
is a sensitive sensor for redox states in the cytosol. In 3T3L1 adipocytes, the knockdown of Gal-9 resulted in lower 
PRDX2 dimer/monomer ratio in the presence of  H2O2, suggesting the amelioration of oxidative stress in cytosol. 
Furthermore, it can be speculated that the disruption of the binding between Gal-9 and PRDX2 by knocking 
down Gal-9 resulted in the facilitation of dimer to monomer conversion by thioredoxin　(Supplementary Fig. 6). 
The oxidative stress induces the insulin resistance associated with increased levels of inflammatory cytokines, 
such as leptin, MCP-1, IL-6, and TNF-α, and recued levels of  adiponectin48. In Gal-9−/− C57BL/6J mice, they 
were resistant to diet-induced obesity and the absence of Gal-9 ameliorated the oxidative stress by shifting lower 
dimer/monomer ratio of PRDX2 in 3T3L1 adipocytes.
In conclusion, Gal-9−/−C57BL/6J mice fed with HFHS chow were resistant to DIO without the alterations in 
production of inflammatory cytokines, M1/M2 macrophage polarization, and formation of crown-like structure. 
Although recombinant Gal-9 is known to induce the apoptosis of Th1 cells and reduction of M1 macrophages, 
the reduction of body weight was independent of BMCs revealed by BMT experiments. Instead, we found that 
Gal-9 binds to PRDX2 and demonstrated that Gal-9 knockdown ameliorated the oxidative stress and reduced 
dimer/monomer ratio of PRDX2 in adipocytes. The inhibition of Gal-9 in adipocytes may be a new therapeutic 
approach targeting the oxidative stress and subsequent insulin resistance in obesity.
Methods
Animals. Lgals9tm1Glp/Lgals9tm1Glp (Gal-9−/−) C57BL/6J mice were kindly provided by GalPharma Co. Ltd. 
Gal-9−/− BALB/c mice were crossed to C57BL/6JJcl mice (CLEA Japan, Tokyo, Japan) for 10 generations. Gal-
9- was detected by PCR primers 5′-GCG AGG CCA GAG GCC ACT TGT GTA GC-3′ and GTG ACA ATA CTG TTC 
CTC TGC AGG -3′, while Lgals9wt (Gal-9wt) by 5′-TGG GGT GTC CTG CAG ACA GCA CAT AA-3′ and 5′-CCA 
GTG CTA CGG CGA CAT AGC CTC -3′. By crossing Gal-9wt/- C57BL/6JJcl mice, we produced Gal-9wt/wt, Gal-9wt/-, 
and Gal-9−/− littermates by standard breeding techniques. Gal-9wt/wt and Gal-9−/− mice were used for the follow-
ing experiments. The 6-week-old male mice were fed with standard chow diet (STD) (MF, Oriental Yeast, Japan) 
or high fat-high sucrose diet (HFHS) (D12331, Research Diets, New Brunswick, NJ), and they were euthanized 
at 28 weeks of age. V̇ ̇O2 and RQ were continuously monitored for 24 h by using  O2/CO2 metabolism measuring 
system (MK-5000, Muromachi, Kyoto, Japan). The locomotor activity was recorded for 24 h by the frequency of 
interrupting an infrared sensor (ACTIMO-100 N, SHINFACTORY, Fukuoka, Japan). IPGTT was performed at 
20–22 weeks of age after 12 h fasting, blood glucose and plasma insulin levels were measured (Skylight Biotech, 
Tokyo, Japan). At 28 weeks of age, sera and tissue samples were collected and weighed after 12 h fasting. Serum 
leptin, adiponectin (ELISA), cholesterol, triglyceride, non-esterified free fatty acid (HPLC), liver cholesterol 
and liver triglyceride (Folch’s method) were measured by Skylight Biotech, Tokyo. All animal experiments were 
approved by the Animal Care and Use Committee of the Department of Animal Resources, Advanced Science 
Research Center, Okayama University. All animal experiments were performed in accordance with relevant 
guideline and regulations.
Immunofluorescence. Epididymal adipose tissues were first stained with rat anti-mouse F4/80 and rabbit 
anti-mouse perilipin, and subsequently stained with goat anti-rat IgG (Alexa Fluor 488) and donkey anti-rabbit 
IgG (Alexa Fluor 555), respectively (Invitrogen). Nuclear stain was performed by DAPI.
Quantitative real-time PCR. Total RNAs from epididymal fat tissue were extracted from using RNe-
asy Lipid Tissue Mini Kit (Qiagen), cDNAs were generated using the High Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems). Quantitative real-time PCR was performed by using Step One Plus Real-Time 
PCR System (Applied Biosystems), Universal Master Mix II (Life Technologies) and TaqMan Gene Expression 
Assays with specific primers; Adgre1 (Mm00802529_m1), Arg1 (Mm00475988_m1), Il6 (Mm00446190_m1), 
Il10 (Mm001288386_m1), Il18 (Mm00434225_m1), Mrc1 (Mm00485148_m1), Nos2 (Mm00440502_m1), Tnf 
(Mm00443258_m1), and Ym1 (Chil3) (Mm00657889_m1).
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Flow cytometry analysis. Mature adipocytes and stromal vascular fractions (SVF) were isolated as 
described below. Epididymal fat tissues were minced and incubated in a fresh digesting media of Krebs Ringer 
HEPES (KRH) buffer for 60 min at 37 °C and were separated into adipocytes and SVF by using mesh with a 
grid diameter 300  µm. The SVF cells were subjected flow cytometry analysis as previously  described30. The 
cells were first incubated at 4 °C for 10 min with Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block) 
(BD Pharmingen) to reduce nonspecific binding of antibodies to FcR receptors. The cells (1 ×  106) derived from 
epididymal fat tissues were incubated at 4 °C for 30 min in Stain Buffer (BD Pharmingen) with the relevant 
optimized amount of fluorochrome conjugated antibodies or the appropriate isotype controls: PerCP-Cy 5.5 Rat 
Anti-Mouse CD11b, BV421 Hamster Anti-Mouse CD11c, PE-Cy 7 Mouse Anti-Mouse CD45.2 (BD Pharmin-
gen), Rat Anti-Mouse CD206 Alexa Fluor 647 (AbD Serotec), and Anti-Mouse F4/80 Antigen FITC (eBiosci-
ence). Dead cells were excluded from analysis using 7-aminoactinomycin D staining (BD pharmigen). All data 
were acquired with FACSAria I flow cytometer (BD Biosciences) and analysed using FlowJo software (TreeStar, 
Ashland, OR).
Bone marrow transplantation. Mice received bone marrow transplantation by the standard protocols as 
previously  described49. In brief, the donor bone marrow cells were obtained from the long bones of 10–12 weeks 
old Gal-9wt/wt (n = 3) and Gal-9−/− (n = 2) C57BL/6JJcl mice. T-cell depletion was performed with anti-CD90.2 
Microbeads and an AutoMACS system (Miltenyi Biotec, Bergisch Gladbach, Germanry) according to the manu-
facturer’s instructions. The recipient 4–6 weeks old Gal-9wt/wt (n = 6) and Gal-9−/− (n = 6) C57BL/6JJcl mice were 
given 5.5 Gy whole body irradiation twice. Then, the recipient mice were injected with 5 ×  106 T cell-depleted 
bone marrow cells from donors. The mice were fed with HFHS for additional 18 weeks.
Immunoprecipitation and nanoLC-MS/MS analysis. Epididymal fat tissues (200 mg each) derived 
from Gal-9wt/wt C57BL/6JJcl mice were minced, lysed in 500  μl of RIPA buffer (Thermo Scientific) contain-
ing 1 mM DTT under reducing condition, and immunoprecipitated with Protein G Immunoprecipitation kit 
(Sigma) by using anti-galectin-9 (Biolegend, Cat#137,902) or Purified rat IgG2a, κ isotype control (Biolegend, 
Cat#400,502) antibodies. The immunoprecipitated protein complexes were electrophoresed in SuperSep Ace 
15–20% Tricine Gel (GE Healthcare), and gel-digested with trypsin. The samples were lyophilized, suspended 
in 20 μl of 0.1% formic acid, and subjected to nanoLC-MS/MS using UltiMate 3000 HPLC, Q-Exactive Plus, 
and Xcalibur (Thermo Scientific). The proteins were searched and identified by Mascot (Matrix Science, Boston, 
MA). The scores by Mowse scoring algorithm, hit peptide fragment numbers, the exponentially modified pro-
tein abundance index (emPAI) were analysed. The gene annotation was performed by PANTHER 15.0 (http://
www.panth erdb.org/).
The lysates from epididymal fat tissues of Gal-9wt/wt and Gal-9−/− C57BL/6JJcl mice were also immunopre-
cipitated with anti-peroxiredoxin 2 (PRDX2) antibody (abcam, Cat#ab109367), and subjected with Western blot 
analysis with anti-galectin-9 antibody (Biolegend, Cat#137,902).
Pull-down assay. Full-length cDNA of peroxiredoxin 2 was amplified by primers; 5′-GGG GGG CTC GAG 
ATG GCC TCC GGC AAC GCG CA-3′ and 5′-GGG GGG GGA TCC TCA GTT GTG TTT GGA GAA GT-3′. The 
PCR products were digested with restriction enzymes, XhoI and BamHI, and ligated to FLAG-HA-pcDNA3.1 
(Addgene, Plasmid #52,535). The plasmid (PRDX2-FLAG-HA-pcDNA3.1) was transfected 3T3L1 cells and 
lysed in RIPA buffer (Thermo Scientific) containing 1 mM DTT in the presence and absence of 0.2 M lactose. 
HA-tagged protein purified by HA-tagged Protein Purification Kit (MBL, Tokyo, Japan). They were subjected to 
SDS-PAGE with 1 mM DTT under reducing condition, and Western blot analysis using anti-galectin-9 antibody 
(Biolegend, Cat#137,902), anti-peroxiredoxin 2 (PRDX2) antibody (abcam, Cat#ab109367), anti-thioredoxin 
(proteintech, Cat#14,999–1-AP), and anti-HA antibody (MBL, Cat#561).
3T3L1 culture and siRNA experiments. 3T3L1 cells (ATCC) were cultured in Dulbecco’s Modi-
fied Eagle’s Medium (Thermo Fisher Scientific) containing 10% fetal bovine serum and they were transfected 
with Silencer select Pre-designed siRNA Lgals9 (Gal-9 siRNA) and silencer select negative control siRNA (NC 
siRNA) (Thermo Fisher Scientific, Cat#s69189) by Lipofectamine RNAi MAX (Cat#13,778,030). After 40 h, the 
3T3L1 cells were further cultured for 20.
minutes in the absence and presence of 10 μM  H2O2. The cells were lysed in 500 μl of RIPA buffer and subject 
to SDS-PAGE under non-reducing conditions and Western blot analysis using anti-galectin-9 antibody (Biole-
gend, Cat#137,902), anti-peroxiredoxin 2 (PRDX2) antibody (abcam, Cat#ab109367), anti-GAPDH antibody 
(Cell Signaling Technology, Cat#8884), anti-phospho-p38 MAPK (Thr180/Try182) antibody (Cat#9211), anti-
p38 MAPK antibody (Cat#9212), anti-phospho-SAPK/JNK (Thr183/Try185) antibody (Cat#9251), anti-SAPK/
JNK antibody (Cat#9252), anti-phospho-p44/42 MAPK (Erk1/2)(Thr202/Try204) antibody (Cat#9101), and 
anti-p44/42 MAPK (Erk1/2) antibody (Cat#9101).
Statistical analysis. All results are expressed as means ± standard deviation (SD). Normal distribution was 
confirmed by Shapiro–Wilk test. Only plasma insulin concentration and percentage of M1 and M2 macrophage 
did not follow the normal distribution. For parametric analyses, the multiple comparisons were performed by 
one-way ANOVA with Tukey–Kramer method and two-pair comparisons by Student’s t test using SPSS software 
(IBM, Chicago, IL). For non-parametric analyses, the multiple comparisons were performed by Kruskal–Wallis 
test with Bonferroni correction. A value of p < 0.05 was regarded as statistically significant.
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